www.fdanews.com/articles/202405-qorvo-biotechnologies-earns-eua-for-rapid-covid-19-antigen-test
Qorvo Biotechnologies Earns EUA for Rapid COVID-19 Antigen Test
April 20, 2021
Greensboro, N.C.-based Qorvo Biotechnologies has received FDA Emergency Use Authorization (EUA) for its rapid Omnia SARS-CoV-2 Antigen Test.
The test platform, which includes a portable test instrument and microfluidic cartridge, is authorized for using nasal swabs to qualitatively detect the presence of SARS-CoV-2 viral antigens.
The rapid test uses high-frequency acoustic wave sensors to deliver results in approximately 20 minutes.